Allosteric MKP5 Inhibitor Compounds for Selective Fibrosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel compounds and compositions that can specifically inhibit MAPK phosphatases (MKPs) to treat, ameliorate, and/or prevent fibrotic diseases or disorders.
Innovation Solution
Development of compounds that inhibit MKP5 through an allosteric mode of action, targeting the catalytic domain of MKP5 and disrupting its interaction with MAPK substrates, thereby regulating MAPK activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional MKP inhibitors are used, then MAPK activity can be modulated, but they lack specificity and cannot selectively target MKP5
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target the unique structural features of MKP5's catalytic domain. The compounds contain functional groups positioned to interact with specific residues (e.g., His43, Asp44, Ser45, Thr46) that are characteristic of MKP5, allowing selective inhibition of this particular phosphatase isoform while sparing other MKP family members with different sequence contexts
Solution Approach 2:
The patent employs an intermediary approach by using the catalytic domain of MKP5 as a mediator to achieve selective inhibition. The compounds are designed to bind specifically to the catalytic domain, which serves as the intermediary interface between the inhibitor and the full-length MKP5 enzyme, enabling selective modulation of MKP5 activity without affecting other phosphatases
2Object-affected harmful factors
If broad-spectrum phosphatase inhibitors are used, then general phosphatase activity is reduced, but they cause off-target effects and cannot specifically treat fibrotic diseases
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features that match the local structural environment of MKP5's catalytic domain. The compounds contain functional groups positioned to form specific interactions (hydrogen bonds, hydrophobic interactions, ionic bonds) with residues unique to MKP5, ensuring that only MKP5 is inhibited while other phosphatases with different local structures remain unaffected
Solution Approach 2:
The patent employs inversion by targeting the catalytic domain directly rather than attempting to inhibit the full-length enzyme through allosteric sites or other indirect mechanisms. By designing compounds that bind to the catalytic domain's active site, the invention achieves specific MKP5 inhibition and thereby selective treatment of fibrotic diseases without the off-target effects associated with broad-spectrum inhibitors
Data Source
AI summary
The present invention provides compounds and methods for treating MKP5 modulated disease. In certain embodiments, the MKP5 modulated disease is a fibrotic disease.